. * * window.aa needs to exist and be usable by ANY module's script, * however early it runs - main-nav's script, for one, runs near * the top of

91探花

, well before the real search-insights.js * so the download * begins as early as before. Repeat calls share the same downloads, a * failed load is retried on the next call, and the versions / SRI * hashes live only here. * * Algolia Insights is unaffected: window.aa above is still created in * on every page and queues events until search-insights loads. * * window.loadAlgoliaLibs({ priority: 'high' }) (Oct 2026): used by the * /search page, where the first results wait on these libraries. Chrome * gives async scripts low priority, behind images and fonts; this asks * for high instead (fetchpriority). Only the first call for a library * sets its priority - later calls share that download. */ (function (win, doc) { var LIBS = [ { ready: function () { return !!win['algoliasearch/lite']; }, src: 'https://cdn.jsdelivr.net/npm/algoliasearch@5.52.1/dist/lite/builds/browser.umd.js', integrity: 'sha256-I2oYUIvhx1g6l4lTP+yoERbzLIHKzw4AKaBRQPwIeDY=' }, { ready: function () { return !!win.instantsearch; }, src: 'https://cdn.jsdelivr.net/npm/instantsearch.js@4.98.0/dist/instantsearch.production.min.js', integrity: 'sha256-ngmqZk4WBxUw257aMYZayyNBd983INngagv0jI6Ecfs=' } ]; function loadOne(lib, options) { if (lib.ready()) return Promise.resolve(); // One download per library, shared by every caller; reset on // failure so the next call retries just the library that failed. if (lib.pending) return lib.pending; lib.pending = new Promise(function (resolve, reject) { var script = doc.createElement('script'); script.src = lib.src; script.integrity = lib.integrity; script.crossOrigin = 'anonymous'; script.async = true; if (options && options.priority === 'high') script.setAttribute('fetchpriority', 'high'); script.onload = function () { lib.ready() ? resolve() : reject(new Error('Loaded but not available: ' + lib.src)); }; script.onerror = function () { script.remove(); reject(new Error('Could not load ' + lib.src)); }; doc.head.appendChild(script); }); lib.pending.catch(function () { lib.pending = null; }); return lib.pending; } win.loadAlgoliaLibs = function (options) { return Promise.all(LIBS.map(function (lib) { return loadOne(lib, options); })); }; })(window, document); . */ window.hsConversationsSettings = window.hsConversationsSettings || {}; window.hsConversationsSettings.loadImmediately = false; (function (win) { var EVENTS = ['pointerdown', 'keydown', 'touchstart', 'scroll', 'mousemove', 'wheel']; var done = false; /* 19 Oct 2026 - chat widget layout shift (field CLS). Phones fail Core Web Vitals on CLS (p75 ~0.2 site-wide in CrUX for months). Biggest cause found: HubSpot's chat container is fixed to the bottom-right corner and changes size - 100x96 launcher to 282x253 when the welcome message pops up (~5 s after load), and to full screen when a visitor opens the chat. Its top-left corner moves, so Chrome scores it as a layout shift: 0.088 per page view at 360x640 (0.044 at 412x850), on every page. Taps happen inside the chat iframe, so the parent page never sees the input and the open/close shifts count too. Fix: whenever the container's size changes it is made transparent for 400 ms (Chrome doesn't score shifts of invisible elements), then shown again at its new size. Tested on live io1001 at 360x640 in a cookie-less frame: the 0.088 shift no longer appears. The chat itself is unchanged - it just appears 0.4 s later at each resize. Relies on HubSpot's container id; if that changes this does nothing (no error). */ function cloakChatResizes() { var ID = 'hubspot-messages-iframe-container'; function watch(c) { if (c.getAttribute('data-bb-cloak')) return; c.setAttribute('data-bb-cloak', '1'); var last = c.offsetWidth + 'x' + c.offsetHeight, timer = null; new MutationObserver(function () { var size = c.offsetWidth + 'x' + c.offsetHeight; if (size === last) return; last = size; c.style.setProperty('opacity', '0', 'important'); clearTimeout(timer); timer = setTimeout(function () { c.style.removeProperty('opacity'); }, 400); }).observe(c, { attributes: true, attributeFilter: ['style', 'class'], subtree: true, childList: true }); } var found = document.getElementById(ID); if (found) { watch(found); return; } if (!document.body || !('MutationObserver' in win)) return; var mo = new MutationObserver(function () { var c = document.getElementById(ID); if (c) { mo.disconnect(); watch(c); } }); mo.observe(document.body, { childList: true }); setTimeout(function () { mo.disconnect(); }, 30000); } function loadWidget() { var api = win.HubSpotConversations; if (api && api.widget && api.widget.status && api.widget.status().loaded) return; try { cloakChatResizes(); } catch (e) {} if (api && api.widget) api.widget.load(); } function onFirstInteraction() { if (done) return; done = true; EVENTS.forEach(function (type) { win.removeEventListener(type, onFirstInteraction, { passive: true }); }); var start = function () { if (win.HubSpotConversations) loadWidget(); else (win.hsConversationsOnReady = win.hsConversationsOnReady || []).push(loadWidget); }; if ('requestIdleCallback' in win) win.requestIdleCallback(start, { timeout: 1500 }); else setTimeout(start, 200); } EVENTS.forEach(function (type) { win.addEventListener(type, onFirstInteraction, { passive: true }); }); })(window);

91探花

Skip to main content
Home
Resources
Case Studies
Improving physiological relevance in neurological disease drug development
Case study

Improving physiological relevance in neurological disease drug development | How Concept Life Sciences is building more reliable, consistent in vitro assays using ioMicroglia

In this case study, hear from Elise Malavasi, Ph.D., a Principal Scientist at leading contract research organisation Concept Life Sciences. The interview highlights their need to develop assays that are amenable to long term use to support their clients with drug development, and how 91探花鈥檚 male donor-derived ioMicroglia has helped them develop assays with increased physiological relevance and consistency towards this goal.
Improving physiological relevance in neurological disease drug development | How Concept Life Sciences is building more reliable, consistent in vitro assays using ioMicroglia

Elise Malavasi, Ph.D

Principal Scientist

Concept Life Sciences

Improving physiological relevance in neurological disease drug development | How Concept Life Sciences is building more reliable, consistent in vitro assays using ioMicroglia
In this case study, hear from Elise Malavasi, Ph.D., a Principal Scientist at leading contract research organisation Concept Life Sciences. The interview highlights their need to develop assays that are amenable to long term use to support their clients with drug development, and how 91探花鈥檚 male donor-derived ioMicroglia has helped them develop assays with increased physiological relevance and consistency towards this goal.
Improving physiological relevance in neurological disease drug development | How Concept Life Sciences is building more reliable, consistent in vitro assays using ioMicroglia

Elise Malavasi, Ph.D

Principal Scientist

Concept Life Sciences

In this case study, hear from Elise Malavasi, Ph.D., a Principal Scientist at leading contract research organisation Concept Life Sciences, where she specialises in the development and use of in-vitro assays for neurobiological research. Of particular interest to Elise is the development of functional assays for microglia, a cell type that is increasingly viewed as a therapeutic target in neurodegenerative disease. The interview highlights their need to develop assays that are amenable to long term use to support their clients with drug development, and how 91探花鈥檚 male donor-derived ioMicroglia has helped them develop assays with increased physiological relevance and consistency towards this goal.

Until now, such consistency has been challenging to develop with primary cell lines, and from human induced pluripotent stem cell (hiPSC) derived cells generated using directed differentiation. They鈥檝e found 91探花鈥檚 ioMicroglia to be highly functional and, critically, to be consistent lot to lot. Elise鈥檚 team is now exploring the use of ioMicroglia in more complex model systems. This work opens the door for Concept Life Sciences to offer more human-relevant models to their clients and better support CNS-targeted drug development.

In this case study you will learn:

  • How Concept Life Sciences seek to develop assays proving drug candidate efficacy on human iPSC-derived microglia
  • How ioMicroglia offered Concept Life Sciences functional cells with low inter-lot variability, ensuring consistent assay performance, facilitating large scale screening studies. 
  • How Concept Life Science鈥檚 initial challenges integrating this new cell type into their workflows were overcome by support from the 91探花 team, ensuring they could easily develop assays using these cells.
V1
2024
91探花 | Concept Life Sciences

Related pages

91探花 Learn about our range of human iPSC-derived cells for research and drug discovery
Our platform Discover the cell coding platform behind our cells
Contact us Talk to us to learn more about our team and products